Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection

Journal of Clinical Investigation

Volumn 121, Issue 7, 2011, Pages 2534-2542

  Jones, Dallas ^a,b   Glimcher, Laurie H ^a,b,c,d   Aliprantis, Antonios O ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AIN 457; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CONJUGATED ESTROGEN; DENOSUMAB; ESTRADIOL; ETANERCEPT; IBANDRONIC ACID; INFLIXIMAB; INTERLEUKIN 17; LY 2439821; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PROTEIN INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RISEDRONIC ACID; TOCILIZUMAB; UNCLASSIFIED DRUG; USTEKINUMAB; ZOLEDRONIC ACID;

ARTHRITIS; BONE ATROPHY; BONE LESION; BONE TURNOVER; CARCINOGENESIS; DRUG TARGETING; HOST RESISTANCE; HUMAN; IMMUNOLOGY; INFECTION; JAW OSTEONECROSIS; METASTASIS; MULTIPLE MYELOMA; MYELOMA CELL; NEOPLASM; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOIMMUNOLOGY; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANIMALS; ARTHRITIS; HUMANS; IMMUNE SYSTEM; INFECTION; INTERLEUKIN-17; NEOPLASMS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS; RANK LIGAND;

EID: 79959941928     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI46262     Document Type: Review

References (127)

1. Zelzer E, Olsen BR. The genetic basis for skeletal diseases. Nature. 2003;423(6937):343-348. (Pubitemid 40852709)
2. Zaidi M. Skeletal remodeling in health and disease. Nat Med. 2007;13(7):791-801. (Pubitemid 47038187)
3. Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell. 2002;2(4):389-406. (Pubitemid 34436569)
4. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol. 2009;5(12):667-676.
5. Wong BR, et al. TRANCE, a new tumor necrosis factor (TNF) family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med. 1997;186(1):1-6.
6. Wong BR, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem. 1997;272(40):25190-25194. (Pubitemid 27415705)
7. Kong YY, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315-323.
8. Kim N, Odgren PR, Kim DK, Marks SC Jr, Choi Y. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci U S A. 2000;97(20):10905-10910.
9. Villa A, Guerrini MM, Cassani B, Pangrazio A, Sobacchi C. Infantile malignant, autosomal recessive osteopetrosis: the rich and the poor. Calcif Tissue Int. 2009;84(1):1-12.
10. Asagiri M, et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med. 2005;202(9):1261-1269. (Pubitemid 41586956)
11. Aliprantis AO, et al. NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest. 2008;118(11):3775-3789.
12. Takayanagi H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3(6):889-901. (Pubitemid 35460788)
13. Negishi-Koga T, Takayanagi H. Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev. 2009;231(1):241-256.
14. Leibbrandt A, Penninger JM. Novel functions of RANK(L) signaling in the immune system. Adv Exp Med Biol. 2010;658:77-94.
15. Sweeney SE, Firestein GS. Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol. 2004;36(3):372-378. (Pubitemid 37542434)
16. Noss EH, Brenner MB. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev. 2008;223:252-270. (Pubitemid 351986192)
17. Heller JE, Shadick NA. Outcomes in rheumatoid arthritis: incorporating the patient perspective. Curr Opin Rheumatol. 2007;19(2):101-105. (Pubitemid 46208765)
18. Singh JA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2009;(4):CD007848.
19. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev. 2010;(7):CD008331.
20. Karmakar S, Kay J, Gravallese EM. Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention. Rheum Dis Clin North Am. 2010;36(2):385-404.
21. Pettit AR, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol. 2001; 159(5):1689-1699. (Pubitemid 33062512)
22. Redlich K, et al. Osteoclasts are essential for TNFα-mediated joint destruction. J Clin Invest. 2002;110(10):1419-1427. (Pubitemid 35396913)
23. Kong YY, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402(6759):304-309.
24. Sims NA, et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum. 2004;50(7):2338- 2346. (Pubitemid 38924414)
25. Herrak P, et al. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum. 2004;50(7):2327-2337. (Pubitemid 38924413)
26. Jarrett SJ, et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum. 2006;54(5):1410-1414.
27. Cohen SB, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58(5):1299-1309. (Pubitemid 351705919)
28. Adamopoulos IE, Bowman EP. Immune regulation of bone loss by Th17 cells. Arthritis Res Ther. 2008;10(5):225.
29. Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun. 1999;265(1):144-150.
30. Kotake S, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 2001;44(5):1003-1012. (Pubitemid 32433604)
31. Takayanagi H, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature. 2000;408(6812):600-605.
32. Kotake S, et al. IFN-γ-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL. Eur J Immunol. 2005;35(11):3353-3363. (Pubitemid 41672539)
33. Gao Y, et al. IFN-γ stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest. 2007;117(1):122-132. (Pubitemid 46048459)
34. Kotake S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. 1999;103(9):1345-1352. (Pubitemid 29218305)
35. Sato K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006;203(12):2673-2682. (Pubitemid 44833343)
36. Hueber W, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72.
37. Genovese MC, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010;62(4):929-939.
38. Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther. 2009;22(1):56-60.
39. Takayanagi H, et al. Involvement of receptor activator of nuclear factor-κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000;43(2):259-269. (Pubitemid 30395733)
40. Takayanagi H, et al. A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. Biochem Biophys Res Commun. 1997;240(2):279-286. (Pubitemid 27523651)
41. Gravallese EM, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000;43(2):250-258. (Pubitemid 30395732)
42. Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology (Oxford). 2006;45(9):1068-1076. (Pubitemid 44542091)
43. Zaiss MM, et al. Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum. 2007;56(12):4104-4112. (Pubitemid 350262338)
44. Zaiss MM, et al. Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol. 2010;184(12):7238-7246.
45. Kelchtermans H, Geboes L, Mitera T, Huskens D, Leclercq G, Matthys P. Activated CD4+CD25+ regulatory T cells inhibit osteoclastogenesis and collagen-induced arthritis. Ann Rheum Dis. 2009;68(5):744-750.
46. Axmann R, et al. CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis. 2008;67(11):1603-1609.
47. Kremer JM, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008;58(4):953-963. (Pubitemid 351563996)
48. Kim YG, Lee CK, Nah SS, Mun SH, Yoo B, Moon HB. Human CD4+CD25+ regulatory T cells inhibit the differentiation of osteoclasts from peripheral blood mononuclear cells. Biochem Biophys Res Commun. 2007;357(4):1046-1052. (Pubitemid 46693677)
49. Tunyogi-Csapo M, et al. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption. Arthritis Rheum. 2008; 58(8):2397-2408.
50. Hashizume M, Hayakawa N, Mihara M. IL-6 transsignaling directly induces RANKL on fibroblastlike synovial cells and is involved in RANKL induction by TNFα and IL-17. Rheumatology (Oxford). 2008;47(11):1635-1640.
51. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNFα osteoclastogenesis. J Clin Invest. 2005;115(2):282-290.
52. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNFα induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000;106(12):1481- 1488. (Pubitemid 32038586)
53. Adamopoulos IE, et al. Interleukin-17A upregulates receptor activator of NFκB on osteoclast precursors. Arthritis Res Ther. 2010;12(1):R29.
54. Goldring SR. Bone and joint destruction in rheumatoid arthritis: what is really happening? J Rheumatol Suppl. 2002;65:44-48.
55. Walsh NC, et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res. 2009;24(9):1572-1585.
56. Diarra D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13(2):156-163.
57. Semenov MV, Tamai K, Brott BK, Kuhl M, Sokol S, He X. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr Biol. 2001;11(12):951-961. (Pubitemid 32589186)
58. Glass DA 2nd, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8(5):751-764.
59. Heiland GR, et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis. 2010;69(12):2152-2159.
60. Heaney RP, et al. Peak bone mass. Osteoporos Int. 2000;11(12):985-1009. (Pubitemid 32144591)
61. Riggs BL, Melton LJ 3rd. Involutional osteoporosis. N Engl J Med. 1986;314(26):1676-1686. (Pubitemid 16097845)
62. Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23(3):279-302. (Pubitemid 34651948)
63. Syed F, Khosla S. Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun. 2005;328(3):688-696. (Pubitemid 40214350)
64. Gass M, Dawson-Hughes B. Preventing osteoporosis-related fractures: an overview. Am J Med. 2006;119(4 suppl 1):S3-S11.
65. Riggs BL, Khosla S, Melton LJ 3rd. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in post-menopausal women and contributes to bone loss in aging men. J Bone Miner Res. 1998;13(5):763-773. (Pubitemid 28224192)
66. Pernis AB. Estrogen and CD4+ T cells. Curr Opin Rheumatol. 2007;19(5):414-420. (Pubitemid 47344231)
67. Cenci S, et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest. 2000;106(10):1229-1237.
68. D'Amelio P, et al. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone. 2008;43(1):92-100.
69. Yoneda T, et al. Estrogen deficiency accelerates murine autoimmune arthritis associated with receptor activator of nuclear factor-kappa B ligand-mediated osteoclastogenesis. Endocrinology. 2004;145(5):2384-2391. (Pubitemid 38535068)
70. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003;111(8):1221-1230. (Pubitemid 36519939)
71. Yamaza T, et al. Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS One. 2008;3(7):e2615.
72. Pacifici R. T cells: critical bone regulators in health and disease. Bone. 2010;47(3):461-471.
73. Lee SK, et al. T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy. J Bone Miner Res. 2006;21(11):1704-1712.
74. Anginot A, Dacquin R, Mazzorana M, Jurdic P. Lymphocytes and the Dap12 adaptor are key regulators of osteoclast activation associated with gonadal failure. PLoS One. 2007;2(7):e585.
75. Spiegel AM. Pathophysiology of primary hyperparathyroidism. J Bone Miner Res. 1991;6(suppl 2):S15-S17.
76. Gao Y, et al. T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab. 2008;8(2):132-145.
77. Tawfeek H, et al. Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS One. 2010;5(8):e12290.
78. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007;40(6):1434-1446. (Pubitemid 46756429)
79. File E, Deal C. Clinical update on teriparatide. Curr Rheumatol Rep. 2009;11(3):169-176.
80. Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148(6):2635-2643. (Pubitemid 46984775)
81. Calvi LM, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425(6960):841-846. (Pubitemid 37351468)
82. Zhang J, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003;425(6960):836-841. (Pubitemid 37351467)
83. Iwasaki H, Suda T. Cancer stem cells and their niche. Cancer Sci. 2009;100(7):1166-1172.
84. Body JJ, et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 2006;12(4):1221-1228.
85. Vij R, et al. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol. 2009;84(10):650-656.
86. Costa L, Major PP. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol. 2009;6(3):163-174.
87. Callander NS, Roodman GD. Myeloma bone disease. Semin Hematol. 2001;38(3):276-285. (Pubitemid 32717665)
88. Melton LJ 3rd, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res. 2005;20(3):487-493. (Pubitemid 40293498)
89. Choi SJ, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood. 2000;96(2):671-675. (Pubitemid 30463390)
90. Giuliani N, Colla S, Morandi F, Rizzoli V. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment. Haematologica. 2004;89(9):1118-1123. (Pubitemid 39295483)
91. Lee JW, et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood. 2004;103(6):2308-2315. (Pubitemid 38326251)
92. Standal T, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood. 2002;100(8):3002-3007.
93. Berenson JR, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16(2):593-602. (Pubitemid 28135605)
94. Petcu EB, Schug SA, Smith H. Clinical evaluation of onset of analgesia using intravenous pamidronate in metastatic bone pain. J Pain Symptom Manage. 2002;24(3):281-284.
95. Mariani S, et al. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia. 2005;19(4):664-670. (Pubitemid 40521173)
96. Tian E, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003; 349(26):2483-2494. (Pubitemid 38010074)
97. Fulciniti M, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009;114(2):371-379.
98. Fata JE, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2000;103(1):41-50.
99. Schramek D, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468(7320):98-102.
100. Gonzalez-Suarez E, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;468(7320):103-107.
101. Jones DH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006; 440(7084):692-696.
102. Marriott I. Osteoblast responses to bacterial pathogens: a previously unappreciated role for boneforming cells in host defense and disease progression. Immunol Res. 2004;30(3):291-308. (Pubitemid 39546231)
103. Conterno LO, da Silva Filho CR. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev. 2009;(3):CD004439.
104. Graves DT, Li J, Cochran DL. Inflammation and uncoupling as mechanisms of periodontal bone loss. J Dent Res. 2011;90(2):143-153.
105. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373-384.
106. Bar-Shavit Z. Taking a toll on the bones: regulation of bone metabolism by innate immune regulators. Autoimmunity. 2008;41(3):195-203. (Pubitemid 351454989)
107. Keeting PE, et al. Evidence for interleukin-1β production by cultured normal human osteoblast-like cells. J Bone Miner Res. 1991;6(8):827-833.
108. Ishimi Y, et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol. 1990; 145(10):3297-3303.
109. Sakuma Y, et al. Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. Infect Immun. 2000;68(12):6819-6825. (Pubitemid 32463389)
110. He J, Tomlinson R, Coon D, Gulati A, Cowan C. Proinflammatory cytokine expression in cyclooxygenase-2-deficient primary osteoblasts. J Endod. 2007;33(11):1309-1312.
111. Gasper NA, Petty CC, Schrum LW, Marriott I, Bost KL. Bacterium-induced CXCL10 secretion by osteoblasts can be mediated in part through toll-like receptor 4. Infect Immun. 2002;70(8):4075-4082. (Pubitemid 34790915)
112. Bandow K, et al. Molecular mechanisms of the inhibitory effect of lipopolysaccharide (LPS) on osteoblast differentiation. Biochem Biophys Res Commun. 2010;402(4):755-761.
113. Henderson B, Nair SP. Hard labour: bacterial infection of the skeleton. Trends Microbiol. 2003;11(12):570-577. (Pubitemid 37500908)
114. Young AB, Cooley ID, Chauhan VS, Marriott I. Causative agents of osteomyelitis induce death domain - containing TNF - related apoptosis - inducing ligand receptor expression on osteoblasts. Bone. 2011;48(4):857-863.
115. Alexander EH, Rivera FA, Marriott I, Anguita J, Bost KL, Hudson MC. Staphylococcus aureus - induced tumor necrosis factor - related apoptosis - inducing ligand expression mediates apoptosis and caspase- 8 activation in infected osteoblasts. BMC Microbiol. 2003;3:5.
116. Varoga D, et al. Osteoblasts participate in the innate immunity of the bone by producing human β-defensin-3. Histochem Cell Biol. 2009;131(2):207-218.
117. Varoga D, et al. The role of human β-defensin-2 in bone. J Anat. 2008;213(6):749-757.
118. Takami M, Kim N, Rho J, Choi Y. Stimulation by toll-like receptors inhibits osteoclast differentiation. J Immunol. 2002;169(3):1516-1523. (Pubitemid 34809198)
119. Ji JD, et al. Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-γ in human osteoclast precursors. J Immunol. 2009;183(11):7223-7233.
120. Rothe L, et al. Human osteoclasts and osteoclast-like cells synthesize and release high basal and inflammatory stimulated levels of the potent chemokine interleukin-8. Endocrinology. 1998;139(10):4353-4363. (Pubitemid 28513725)
121. Masuda T, Deng X, Tamai R. Mouse macrophages primed with alendronate down-regulate monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha (MIP-1alpha) production in response to Toll-like receptor (TLR) 2 and TLR4 agonist via Smad3 activation. Int Immunopharmacol. 2009;9(9):1115-1121.
122. Li H, Hong S, Qian J, Zheng Y, Yang J, Yi Q. Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. Blood. 2010;116(2):210-217.
123. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144(10):753-761. (Pubitemid 46780635)
124. Li D, et al. Effects of antiresorptive agents on osteomyelitis: novel insights into the pathogenesis of osteonecrosis of the jaw. Ann N Y Acad Sci. 2010;1192:84-94.
125. Bi Y, et al. Bisphosphonates cause osteonecrosis of the jaw-like disease in mice. Am J Pathol. 2010;177(1):280-290.
126. Kendler DL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1):72-81.
127. Miller PD. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep. 2009;7(1):18-22.